272 related articles for article (PubMed ID: 16806871)
1. The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters.
Bryhn M; Hansteen H; Schanche T; Aakre SE
Prostaglandins Leukot Essent Fatty Acids; 2006 Jul; 75(1):19-24. PubMed ID: 16806871
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of marine n-3 fatty acid formulations.
Dyerberg J; Madsen P; Møller JM; Aardestrup I; Schmidt EB
Prostaglandins Leukot Essent Fatty Acids; 2010 Sep; 83(3):137-41. PubMed ID: 20638827
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids.
Rupp H; Wagner D; Rupp T; Schulte LM; Maisch B
Herz; 2004 Nov; 29(7):673-85. PubMed ID: 15580322
[TBL] [Abstract][Full Text] [Related]
4. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters.
Neubronner J; Schuchardt JP; Kressel G; Merkel M; von Schacky C; Hahn A
Eur J Clin Nutr; 2011 Feb; 65(2):247-54. PubMed ID: 21063431
[TBL] [Abstract][Full Text] [Related]
5. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson MH; Johnson J; Rooney MW; Kyle ML; Kling DF
J Clin Lipidol; 2012; 6(6):573-84. PubMed ID: 23312053
[TBL] [Abstract][Full Text] [Related]
6. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial.
Hamazaki K; Itomura M; Huan M; Nishizawa H; Sawazaki S; Tanouchi M; Watanabe S; Hamazaki T; Terasawa K; Yazawa K
Nutrition; 2005 Jun; 21(6):705-10. PubMed ID: 15925295
[TBL] [Abstract][Full Text] [Related]
7. [Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers].
Beckermann B; Beneke M; Seitz I
Arzneimittelforschung; 1990 Jun; 40(6):700-4. PubMed ID: 2144420
[TBL] [Abstract][Full Text] [Related]
8. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Offman E; Marenco T; Ferber S; Johnson J; Kling D; Curcio D; Davidson M
Vasc Health Risk Manag; 2013; 9():563-73. PubMed ID: 24124374
[TBL] [Abstract][Full Text] [Related]
9. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
10. Effect of eicosapentaenoic/docosahexaenoic fatty acids and soluble fibers on blood lipids of individuals classified into different levels of lipidemia.
Castro IA; Monteiro VC; Barroso LP; Bertolami MC
Nutrition; 2007 Feb; 23(2):127-37. PubMed ID: 17234506
[TBL] [Abstract][Full Text] [Related]
11. Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio.
Burns T; Maciejewski SR; Hamilton WR; Zheng M; Mooss AN; Hilleman DE
Pharmacotherapy; 2007 May; 27(5):633-8. PubMed ID: 17461697
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
13. Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men.
Yusof HM; Miles EA; Calder P
Prostaglandins Leukot Essent Fatty Acids; 2008 Mar; 78(3):219-28. PubMed ID: 18403189
[TBL] [Abstract][Full Text] [Related]
14. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides.
Sadovsky R; Kris-Etherton P
Postgrad Med; 2009 Jul; 121(4):145-53. PubMed ID: 19641280
[TBL] [Abstract][Full Text] [Related]
15. Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial.
Shimada H; Nilsson C; Noda Y; Kim H; Lundström T; Yajima T
J Atheroscler Thromb; 2017 Sep; 24(9):980-987. PubMed ID: 28344197
[TBL] [Abstract][Full Text] [Related]
16. Microdetermination of fatty acids by gas chromatography and cardiovascular risk stratification by the "EPA+DHA level".
Rupp H; Rupp TP; Wagner D; Alter P; Maisch B
Herz; 2006 Dec; 31 Suppl 3():30-49. PubMed ID: 17575804
[TBL] [Abstract][Full Text] [Related]
17. A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies
Lopez-Toledano MA; Thorsteinsson T; Daak A; Maki KC; Johns C; Rabinowicz AL; Sancilio FD
Clin Ther; 2017 Mar; 39(3):581-591. PubMed ID: 28189364
[TBL] [Abstract][Full Text] [Related]
18. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
Rupp H
Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
[TBL] [Abstract][Full Text] [Related]
19. Circulating fatty acid profiles in response to three levels of dietary omega-3 fatty acid supplementation in horses.
King SS; Abughazaleh AA; Webel SK; Jones KL
J Anim Sci; 2008 May; 86(5):1114-23. PubMed ID: 18192545
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
Maki KC; Johns C; Harris WS; Puder M; Freedman SD; Thorsteinsson T; Daak A; Rabinowicz AL; Sancilio FD
Clin Ther; 2017 Mar; 39(3):652-658. PubMed ID: 28189365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
